主要先進国における抗高血圧治療市場（～2020）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Pathophysiology 8
2.2 Etiology 9
2.3 Signs and Symptoms 9
2.4 Co-Morbidities and Complications 10
2.5 Diagnosis 11
2.5.1 Office Blood Pressure Monitoring 11
2.5.2 Ambulatory Blood Pressure Monitoring 11
2.5.3 Home Blood Pressure Monitoring 11
2.5.4 Miscellaneous Methods 11
2.5.5 Diagnosis of Target Organ Damage 12
2.5.6 Diagnosis of Hypertension in Pregnancy 12
2.6 Classification 12
2.7 Epidemiology 13
2.8 Prognosis 14
2.9 Treatment and Management 14
2.9.1 Treatment Strategy 15
3 Marketed Products 19
3.1 Approved Products 19
3.1.1 Norvasc (amlodipine besylate) – Pfizer 19
3.1.2 Micardis (telmisartan) – Boehringer Ingelheim 21
3.1.3 Tekturna (aliskiren) – Novartis/Speedel 22
3.1.4 Benicar (olmesartan medoxomil) – Daiichi Sankyo 24
3.1.5 Diovan (valsartan) – Novartis 25
3.1.6 Cozaar (losartan) – Merck 27
3.1.7 Exforge (amlodipine + valsartan) – Novartis 29
3.2 Comparative Efficacy and Safety 31
4 Product Pipeline 33
4.1 Overall Pipeline 33
4.2 Pipeline Analysis by Molecules Type 34
4.3 Pipeline Analysis by Mechanism of Action Type 35
4.4 Clinical Trial Failure Rate 37
4.5 Patient Enrollment and Clinical Trial Size 39
4.6 Clinical Trial Duration 40
4.7 Promising Drug Candidates in Pipeline 41
4.7.1 LCZ696 (AHU-377 + valsartan) – Novartis 41
5 Market Forecast 42
5.1 Introduction 42
5.2 Global Market 42
5.3 North America 44
5.3.1 Treatment Usage Patterns 44
5.3.2 Annual Cost of Therapy 45
5.3.3 Market Revenue 46
5.4 Top Five European Countries 47
5.4.1 Treatment Usage Patterns 47
5.4.2 Annual Cost of Therapy 48
5.4.3 Market Revenue 49
5.5 Japan 50
5.5.1 Treatment Usage Patterns 50
5.5.2 Annual Cost of Therapy 50
5.5.3 Market Revenue 51
5.6 Drivers and Barriers 52
5.6.1 Drivers 52
5.6.2 Barriers 52
6 Deals and Strategic Consolidations 54
6.1 Licensing Deals 56
6.1.1 Bristol-Myers Squibb Enters into Licensing Agreement with Kyowa Hakko Kirin for Coniel in China 57
6.1.2 Takeda Pharma Enters into Licensing Agreement with Arbor Pharma for Edarbi and Edarbyclor 57
6.1.3 Lorus Therapeutics Enters into Licensing Agreement with Zor Pharma 57
6.1.4 Nippon Shinyaku Signs Licensing Agreement with Eli Lilly 57
6.2 Co-development Deals 58
6.2.1 AnGes Enters into Co-development Agreement with BioLeaders for Hypertension Vaccine 59
6.2.2 Takeda Enters into Co-development Agreement with Covance 59
6.2.3 Boehringer Ingelheim Enters into an Agreement with Vitae Pharma 59
6.2.4 NicOx Expands Research Collaboration with Merck 59
7 Appendix 60
7.1 Market Forecasts to 2020 60
7.2 All Pipeline Drugs by Phase 63
7.2.1 Discovery 63
7.2.2 Preclinical 64
7.2.3 Phase I 66
7.2.4 Phase II 74
7.2.5 Phase III 77
7.3 Abbreviations 82
7.4 References 84
7.5 Methodology 87
7.5.1 Coverage 87
7.5.2 Secondary Research 88
7.5.3 Primary Research 88
7.5.4 Therapeutic Landscape 88
7.5.5 Geographical Landscape 91
7.5.6 Pipeline Analysis 91
7.6 Expert Panel Validation 91
7.7 Contact Us 91
7.8 Disclaimer 91